FDA warns Alexion on RI manufacturing facility
This article was originally published in Scrip
Executive Summary
Alexion Pharmaceuticals revealed on 28 March it had received a warning letter from the US FDA citing inadequate investigation of bacterial contamination of certain batches of its drugs produced at its Rhode Island manufacturing facility and the failure to ensure compliance with current good manufacturing practices (cGMPs).